News

Since 2009, the two partners have been working together on the development of novel treatment options for cancer patients. Over the next five years, Bayer and DKFZ will

The new patent, US patent No. 8,628,774, covers certain methods of treating cancer with antibodies that bind human leucine-rich repeat-containing G protein-coupled receptor (LGR) proteins and either disrupt

The new Tramore laboratory, which is key to the growth of the company’s DNA sequencing service in Ireland, is positioned between Cork and Dublin, providing an opportunity to

The new deal is focused on the discovery and development of several predefined Nanobody candidates (including bi- and tri-specifics) directed toward ‘immune checkpoint modulators’. Immune checkpoint modulators are

The acquisition gives AstraZeneca ownership of the intellectual property and global rights for the development, manufacture and commercialisation of the diabetes business, including Onglyza, Kombiglyze XR, Komboglyze, dapagliflozin,

The NRC located in Chengdu’s Bio-Technology Park will focus on process and method development of technically challenging specialty injectable pharmaceuticals. The center, which is staffed with an international

Hertraz is a biosimilar to Roche’s Herceptin and is indicated for the treatment of HER2-positive metastatic breast cancer. The drug is available in 440mg and 150mg strengths. The

This patent relates to BrainStorm’s proprietary stem cells induced to secrete large quantities of neurotrophic factors for the treatment of neurodegenerative diseases. Pending approval from the US Food

Ferrer also announced it is collaborating with Ildong Pharmaceuticals, Korea. Ergomed is working with Ferrer as the clinical development organization to conduct the multicenter, multinational, randomized Phase IIa